Sign up to save your podcasts
Or
Share Zepbound vs Wegovy: A two horse race
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Zepbound vs Wegovy: A two horse race
Last week, the FDA approved Eli Lilly's obesity drug Zepbound, creating an anticipated intense competition between it and Novo Nordisk's Wegovy. BioSpace's Greg Slabodkin, Tyler Patchen and Lori Ellis discuss the weight loss race and the future of this drug class.
Plus, a quick recap on Valneva, the FDA's first Chikungunya vaccine approval.
View all episodes
By BioSpace
4.9
1313 ratings
Last week, the FDA approved Eli Lilly's obesity drug Zepbound, creating an anticipated intense competition between it and Novo Nordisk's Wegovy. BioSpace's Greg Slabodkin, Tyler Patchen and Lori Ellis discuss the weight loss race and the future of this drug class.
Plus, a quick recap on Valneva, the FDA's first Chikungunya vaccine approval.
More shows like BioSpace
View all
This American Life
90,994 Listeners
Planet Money
30,666 Listeners
Hidden Brain
43,528 Listeners
Marketplace
8,776 Listeners
Exchanges
970 Listeners
WSJ What’s News
4,345 Listeners
Bloomberg Surveillance
1,170 Listeners
Odd Lots
1,967 Listeners
Up First from NPR
56,508 Listeners
The Indicator from Planet Money
9,532 Listeners
The Readout Loud
337 Listeners
The Journal.
6,089 Listeners
Short Wave
6,564 Listeners
BioCentury This Week
34 Listeners
Biotech Hangout
23 Listeners